MarketWatch

A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer’s drugs that have hit the market in the last few years — really help slow the disease.

After a three-week-long rally that’s brought the S&P 500 to new record highs, investors are again bracing for uncertainty following a whirlwind of weekend developments concerning the war with Iran.

The Iran war may or may not be nearing a conclusion. But as far as the stock market is concerned, it’s no longer been worth worrying about.

Benefit limits could do a lot to solve Social Security’s fiscal problems, CRFB suggests. But check the fine print.